FDA's Accelerated Approval for Folate Treatment in Autism Subgroup Spurs Widespread Off-Label Use Amid Evidence Debate

Understanding the Approval and Prescription Trends

In September 2025, the FDA granted accelerated approval to leucovorin—a synthetic form of folate—specifically for treating cerebral folate deficiency (CFD) in autistic individuals. CFD occurs when antibodies interfere with folate transport across the blood-brain barrier, potentially affecting neurological function. While intended for this specific subgroup, prescriptions for broader autism traits rose 2000% by late 2025, per UC San Diego researchers.

Current Treatment Landscape and Evidence Gaps

No medication is FDA-approved to address social communication differences or repetitive behaviors common in autism. Existing options like risperidone and aripiprazole help manage co-occurring challenges such as emotional dysregulation, notes the Autism Research Institute. Leucovorin’s approval specifically targets CFD, which affects an estimated 5-10% of autistic individuals according to 2024 research in Molecular Psychiatry. While some parents describe marked improvements in communication and focus, JHEOR’s 2025 analysis found these reports lack large-scale validation. A 2016 pilot study (n=48) showed modest language gains in CFD-positive participants, but replication studies are ongoing.

While intended for this specific subgroup, prescriptions for broader autism traits rose 2000% by late 2025, per UC San Diego researchers.

Emerging Approaches and Family Decision-Making

Other investigational approaches include:

• Repurposed medications: Loperamide (an anti-diarrheal) shows preclinical potential by modulating opioid receptors linked to social bonding, per Frontiers in Pharmacology
• Vasopressin nasal spray: Early trials suggest this hormone may affect social processing, though results are mixed (Nature Reviews Drug Discovery, 2025)

Autistic self-advocates emphasize that support needs vary widely. 'We need research that respects neurodivergent communication styles rather than seeking to eliminate them,' notes Autistic Self Advocacy Network policy director Julia Bascom in a 2025 interview. Meanwhile, the leucovorin trend reflects families balancing hope with limited options—a dynamic requiring better biomarkers to predict treatment response, argues Dr. David Amaral in Autism Research.